• Home
  • NEW DAY MEDICINE
  • 2 (52) 2023
  • 13 -2 (52) 2023 — A.A. Khalimov, G.M. Tulaboeva — SPECIFICITY OF THE COURSE OF LIVER DYSFUNCTION IN CHRONIC HEART FAILURE

13 -2 (52) 2023 — A.A. Khalimov, G.M. Tulaboeva — SPECIFICITY OF THE COURSE OF LIVER DYSFUNCTION IN CHRONIC HEART FAILURE

SPECIFICITY OF THE COURSE OF LIVER DYSFUNCTION IN CHRONIC HEART FAILURE

A.A. Khalimov, Center for the development of professional qualifications of medical workers

G.M. Tulaboeva, Center for the development of professional qualifications of medical workers

X.M. Sagatova, Center for the development of professional qualifications of medical workers

Yu.Sh. Talipova, Center for the development of professional qualifications of medical workers

N.M. Abdukadirova, Center for the development of professional qualifications of medical workers

S.Dj. Mominov. Center for the development of professional qualifications of medical workers

Resume

Chronic heart failure is a systemic chronic disease, a number of scientific studies have shown that when it occurs, it affects a number of body organs, including the liver and kidneys. The specificity of the vascular system of the liver and its high metabolic activity make its hemodynamic parameters weak and allow it to cause many molecular and hemodynamic changes. Liver dysfunction is common in patients with chronic heart failure, and these changes are directly related to hemodynamic parameters. Currently, the systematization of the combined state of the heart and liver is being carried out, depending on the primary localization of the pathological process. Cirrhosis of the liver includes a number of clinical, biochemical, histological and hemodynamic disorders. Chronic liver disease is caused by right ventricular and right ventricular heart failure. Alternatively, chronic liver cirrhosis is thought to be caused by elevated central venous pressure, pulmonary hypertension, constrictive pericarditis, and mitral stenosis and tricuspid valve insufficiency.

Key words: chronic heart failure, chronic liver disease, liver dysfunction, cirrhosis of the liver, right ventricular failure of the heart.

First page

73

Last page

78

For citation: A.A. Khalimov, G.M. Tulaboeva, X.M. Sagatova, Yu.Sh. Talipova, N.M. Abdukadirova, S.Dj. Mominov. – SPECIFICITY OF THE COURSE OF LIVER DYSFUNCTION IN CHRONIC HEART FAILURE //New Day in Medicine 2(52)2023 73-78 https://clck.ru/33X4FN

LIST OF REFERENCES:

  1. Allen L., Felker G., Pocock S., et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity(CHARM) program. //Eur. J. Heart Failure, 2009; 11 (2): 170-177. doi: 10.1093/eurjhf/hfn031.
  2. Amin A., Vakilian F., Maleki M. Serum uric acid levels correlate with filling pressures in systolic heart failure. //Congest Heart Fail. 2011; 17: 80-4.
  3. Birrer R., Takuda Y., Takara T. Hypoxic hepatopathy: pathophysiology and prognosis. //Intern. Med. 2007; 46 (14): 1063-1070. doi: 10.2169/internalmedicine.46.0059.
  4. Bhardwaj S.S., Chalasani N.P. Hepatotoxicity of cardiovascular and antidiabetic medications. //In: Drug-Induced Liver Disease. 2nd edn. New York, London: Informa Health Care, 2007: 593-631.
  5. Cogger V.C., Fraser R., Le Couteur D.G., et al. Liver dysfunction and heart failure. //Am. J. Cardiol. 2003; 91:1399.
  6. Friedman L.S. Congestive Hepathopathy. 2010. Version 17.2. http://www.uptodate.com/css/ amages/ui-icones (accessed Jul 2010).
  7. Fuhrmann V., Jager B., Zubkova A., Drolz A. Hypoxic hepatitis – ​epidemio­logy, pathophysiology, and clinical management. //Wien Klin. Wochenschr. 2010; 122 (5-6): 129-139. doi: 10.1007/s00508-010-1357-6.
  8. Jolliffe N. Liver function in congestive heart failure. //J. Clin. Invest. 1930; 8 (3): 419-434. doi:10.1172/JCI100272.
  9. Megalla S., Holtzman D., Aronow W.S., et al. Prediction of cardiac hepato­pathy in patients with right heart failure. //Med. Sci Monit. 2011; 17 (10): 537-541.
  10. Naschitz J., Slobodin G., Lewis R., et al. Heart diseases affecting the liver and liver diseases affecting the heart. //Am. Heart J. 2000; 140 (1): 111-120. doi: 10.1067/mhj.2000.107177.
  11. Pfeffer M., Swedberg K., Granger C., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. //Lancet, 2003; 362 (9386): 759-766. doi: 10.1016/S0140-6736(03)14282-1.
  12. Poelzl G., Eberl C., Achrainer H., et al. Prevalence and prognostic significance of elevated-glutamyltransferase in chronic heart failure. //Circ. Heart Fail. 2009; 2: 294-302.
  13. Ren X., Oei H.H., Pearlman J.D. Cardiac Cirrhosis and Congestive Hepato­pathy Treatment and Management. http://emedicine.medscape.com/­article/151792-overview (accessed 20 Aug 2010).
  14. Saner F.H., Heuer M., Meyer M., et al. When the heart kills the liver: acute liver failure in congestive heart failure. //Eur. J. Med. Res. 2009; 14 (12): 541-546. doi: 10.1186/2047-783X‑14-12-541.
  15. Shinagava H., Inomata T., Koitabashi T., et al. Increased serum bilirubin levels coincident with heart failure decompensation indicate the need for intravenous inotropic agents. //Int. Heart J. 2007; 48: 195-204.
  16. Van Deursen V., Damman K., Hillege H., et al. Abnormal liver function in relation to hemodynamic profile in heart failure patients. //J. Card. Fail. 2010; 16 (1): 84-90.

file

download